

Nastech Pharmaceutical

[View the current Nastech Pharmaceutical Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7345-Nastech+Pharmaceutical.html)

(<http://www.bioportfolio.com/biocorporate/7345-Nastech+Pharmaceutical.html>)

Contact Details:

3830 Monte Villa Parkway

Bothell

Washington

98021

United States of America

Tel: 425-908-3600

Fax: 425-908-3650

Email: ir@nastech.com

Nastech Pharmaceutical Company Inc. is a Formulation Science specialty company that utilizes biophysics, physical chemistry and pharmacology to bridge the gap between drug discovery and drug optimization. Nastech's proprietary Systemic Transnasal Absorption Technology (STA-T™), Paracellular Transport System (PTS™), and Junction Activator Technology (JAT™) provide rapid assessment of the merits of a drug compound for intranasal drug delivery. The Company has a diverse product portfolio across multiple therapeutic areas, including products targeted for the treatment of sexual dysfunction, pain management, cancer and hepatic illnesses, growth deficiency and multiple sclerosis. Nastech is broadening applications for its technology through an aggressive pre-clinical and clinical program involving the intranasal delivery of large-molecule drugs.

Recent Publications by Nastech Pharmaceutical:



- [Development of Calcitonin Salmon Nasal Spray: similarity of peptide formulated in chlorobutanol compared to benzalkonium chloride as preservative.](#)

The similarity of an intranasal salmon calcitonin (sCT) employing... 20th February, 2009

Nastech Pharmaceutical Company, Inc, Bothell, Washington 98021, USA.- J Pharm Sci. 2009 Oct;98(10):3691-706. ([DOI Direct Link](#))

- [Identification of tight junction modulating lipids.](#)

Tight junctions (TJs) play an important role in regulating paracellular... 13th February, 2009

Nastech Pharmaceutical Company, Inc, Bothell, Washington, USA.- J Pharm Sci. 2009 Feb;98(2):606-19. ([DOI Direct Link](#))

- [Intranasal administration of acetylcholinesterase inhibitors.](#)

This short review outlines the rationale, challenges, and opportunities... 3rd February, 2009

Nastech Pharmaceutical Company Inc, 3830 Monte Villa Parkway, Bothell, WA- BMC Neurosci. 2008

Dec 10;9 Suppl 3:S6. ([DOI Direct Link](#))

- [Discovery of tight junction modulators: significance for drug development and delivery.](#)
*Tight junction biology has many important applications, from improving...*20th September, 2008
Nastech Pharmaceutical Company, Inc., 3830 Monte Villa Parkway, Bothell,- Drug Discov Today. 2008 Mar;13(5-6):261-7. Epub 2008 Feb 20. ([DOI Direct Link](#))
- [A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A.](#)
*BACKGROUND: The recent emergence of avian H5N1 influenza virus has led to...*22nd April, 2008
Nastech Pharmaceutical Company, Inc., 3830 Monte Villa Parkway, Bothell,- Expert Opin Biol Ther. 2008 Mar;8(3):299-313. ([DOI Direct Link](#))
- [Phage display screening of epithelial cell monolayers treated with EGTA: identification of peptide FDFWITP that modulates tight junction activity.](#)
*Phage display was used to screen for peptides that modulate the activity...*5th April, 2008
Nastech Pharmaceutical Company, Inc., Bothell, Washington 98021, USA.- J Biomol Screen. 2007 Dec;12(8):1092-101. Epub 2007 Nov 26. ([DOI Direct Link](#))
- [Intranasal delivery: physicochemical and therapeutic aspects.](#)
*Interest in intranasal (IN) administration as a non-invasive route for...*3rd August, 2007
Nastech Pharmaceutical Company, Inc., Bothell, WA 98021, USA.- Int J Pharm. 2007 Jun 7;337(1-2):1-24. Epub 2007 Mar 25. ([DOI Direct Link](#))
- [In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.](#)
*The purpose of the current investigation was to optimize an intranasal...*23rd June, 2007
Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA- Int J Pharm. 2007 Apr 20;335(1-2):138-46. Epub 2006 Nov 16. ([DOI Direct Link](#))
- [The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7.](#)
*Phage libraries displaying linear or disulfide-constrained peptides often...*11th May, 2007
Nastech Pharmaceutical Company, Inc., Bothell, Washington 98021, USA.- J Biol Chem. 2007 Mar 30;282(13):9813-24. Epub 2007 Jan 30. ([DOI Direct Link](#))
- [Advances in nasal drug delivery through tight junction technology.](#)
*New approaches for enhancing intranasal drug delivery based on recent...*16th September, 2006
Nastech Pharmaceutical Company, Inc., Bothell, WA 98021, USA.- Expert Opin Drug Deliv. 2005 Mar;2(2):281-98. ([DOI Direct Link](#))
- [Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.](#)
*Previously, a novel tight junction modulating (TJM) peptide was described...*28th July, 2006
Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell,- J Pharm Sci. 2006 Jun;95(6):1364-71. ([DOI Direct Link](#))
- [Lower mean weight after 14 days intravenous administration peptide YY3-36 \(PYY3-36\) in rabbits.](#)
*OBJECTIVE: Endogenous peptide YY(3-36) (PYY(3-36)) is associated with...*21st July, 2006
Nastech Pharmaceutical Company Inc., Bothell, WA 98021, USA.- Int J Obes (Lond). 2006 Jan;30(1):68-72. ([DOI Direct Link](#))
- [Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.](#)
*The goal of the current study was to develop an intranasal (IN)...*20th January, 2006
Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA- J Pharm Sci. 2005 Aug;94(8):1736-46. ([DOI Direct Link](#))

Press Releases on Nastech Pharmaceutical:

Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market	26th November, 2009	Frost & Sullivan	JOHANNESBURG, South Africa, Nov. 26 /PRNewswire/ -- The 2009 Frost & Sullivan South Africa Company of the Year Award in the Generic Pharmaceutical Market is presented to Cipla Medpro South Africa
Heska Announces Supply Agreement With Roche Diagnostics	25th November, 2009	Heska Corporation	LOVELAND, Colo., Nov. 25 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA); ("Heska"), a leading provider of advanced diagnostic and specialty products to the veterinary industry, HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated
China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits	25th November, 2009	China Sky One Medical, Inc.	WOODCLIFF LAKE, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced the results of its "Modified Dutch Auction" tender offer, in which Par DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer	25th November, 2009	Par Pharmaceutical Companies, Inc.	
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		

BioNews Results for Nastech Pharmaceutical



- [Par Pharmaceutical Receives Final Approval to Market Generic Ultram ER](#)
Pharma Live: Nov 21 2009 1:50PM Matching: pharmaceutical
- [U.S. Food and Drug Administration Approves ABILIFY \(aripiprazole\) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients \(Ages 6 to 17 Years\)](#)
Earthtimes.org: Nov 20 2009 11:57PM Matching: pharmaceutical
- [\(Tentative\) Q4 2009 ALLIANCE PHARMACEUTICAL CORP Earnings Release - ESTIMATED](#)
Reuters: Nov 20 2009 5:02AM Matching: pharmaceutical
- [Right first time drug manufacture](#)
Pharmaceutical Technology: Nov 20 2009 7:05AM Matching: pharmaceutical
- [Research and Markets: Pharmaceutical Market Access, Pricing, and Reimbursement News in the](#)

Second Quarter of 2

Pharmacy Choice: Nov 20 2009 3:03AM Matching: pharmaceutical

- [Week of Nov. 16, 2009: GSK and Nabi Form Nicotine Vaccine Agreement; Eli Lilly Research Exec to Retire; More](#)

Pharmaceutical Technology: Nov 19 2009 3:51PM Matching: pharmaceutical

- [Pharmaceutical Industry In India Records High Growth](#)

GantDaily.com: Nov 19 2009 2:28PM Matching: pharmaceutical

- [Research and Markets: Pharmaceutical Contract Manufacturing - Global Market Trends](#)

Forbes.com: Nov 19 2009 1:50PM Matching: pharmaceutical

- [Research and Markets: Pharmaceutical Contract Manufacturing - Global Market Trends](#)

PR inside: Nov 19 2009 1:46PM Matching: pharmaceutical

- [Research and Markets: Pharmaceutical Contract Manufacturing - Global Market Trends](#)

PR inside: Nov 19 2009 1:45PM Matching: pharmaceutical

- [Pharmaceutical journals](#)

Research Information: Nov 18 2009 2:02PM Matching: pharmaceutical

- [Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. S](#)

Journal of Chemical Information and Modeling: Nov 18 2009 5:49PM Matching: pharmaceutical

- [Pharmaceutical company challenged NHS ruling](#)

Irish Medical Times: Nov 18 2009 7:06PM Matching: pharmaceutical

- [Cloud Computing Fuels Rapid Growth for Cycle Computing](#)

Ulitzer: Nov 18 2009 5:39AM Matching: pharmaceutical

- [Purdue Pharma sues Sun Pharma following Para IV patent filing on pain killer drug](#)

PharmaBiz: Nov 17 2009 2:55AM Matching: pharmaceutical

Nastech Pharmaceutical Clinical Trials:



- [A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects](#)

Nastech Pharmaceutical Patents:



- 7329725- [Phage displayed Trp cage ligands](#)
- 6436950- [Nasal delivery of apomorphine](#)
- 6225343- [Compositions and methods comprising morphine gluconate](#)
- 5874450- [Intranasal formulations for promoting sleep and method of using the same](#)
- 5770618- [Method for increasing the solubility of clemastine and pharmaceutical compositions prepared therefrom](#)

- 4778810- [Nasal delivery of caffeine](#)
- 4749700- [Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same](#)
- 4729997- [Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same](#)
- 4724231- [Nasal compositions containing vitamin B.sub.12](#)
- 6451848- [Compositions and methods comprising morphine gluconate](#)
- 6599883- [Nasal delivery of xylitol](#)
- 7229966- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7229636- [Cyanocobalamin low viscosity aqueous formulations for intranasal delivery](#)
- 7186692- [Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7186691- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7166575- [Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity](#)
- 7157426- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 6740660- [Nasal delivery of apomorphine](#)
- 6677346- [Methods comprising intranasal morphine](#)
- 4624965- [Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

